Objective: Our main aim was to investigate the serum lipid levels in a series of patients with liver cirrhosis of viral origin. Subjects and Methods: The study comprised 90 patients, 60 with viral liver cirrhosis, equally divided between hepatitis virus C (HCV) and B (HBV) etiologies, and 30 control patients with no known liver pathology. Patients were investigated during a 5-year period in the 1st Medical Clinic of the Emergency County Hospital of Craiova, Romania. The following series of serum lipid parameters were recorded: lipemia, total cholesterol and cholesteryl ester, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol and triglyceride (TG) values. Statistical analysis of these parameters was performed using the ANOVA test followed by Tukey multiple comparison tests to compare replicate means; p < 0.05 was considered statistically significant. Results: We observed significantly lower values for serum lipids (543.5 and 549.37 mg/dl in the HBV and HCV cirrhosis subgroups, compared with 649.9 mg/dl in controls), total cholesterol (143.6 and 147.9 vs. 198.0 mg/dl, respectively), cholesteryl esters (83.6 and 80, compared to 147.9 mg/dl, respectively), LDL cholesterol (91.6 and 88.5 vs. 132.4 mg/dl) in both cirrhosis groups when compared with controls (p < 0.001), as well as HDL cholesterol (32.1 and 36.9 vs. 47.3 mg/dl, p < 0.05). However, TG and VLDL cholesterol values of controls and cirrhosis groups were similar (p > 0.05). We did not register any differences between the two cirrhosis groups (p > 0.05). Conclusion: Our data showed that both HCV and HBV cirrhosis severely impaired liver lipid metabolism. Late stages of the disease resulted in a pseudonormalization of VLDL cholesterol and TG values.

Keywords:
Serum lipids, Viral hepatitis, Cirrhosis
1.
Nguyen P, Leray V, Diez M, Serisier S, Le Bloc’h J, Siliart B, Dumon H: Liver lipid metabolism. J Anim Physiol Anim Nutr 2008;92:272–283.
2.
Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L: Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792–796.
3.
Cimminiello C, Soncini M, Gerosa MC, Toschi V, Motta A, Bonfardeci G: Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group. Biomed Pharmacother 1995;49:364–368.
4.
Jarmay K, Karacsony G, Nagy A, Schaff Z: Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 2005;11:6422–6428.
5.
Kaye GL, Kruszynska YT, Harry DS, Heslop K, Johnston DG, McIntyre N: Lipid metabolism and insulin resistance in cirrhosis. J Hepatol 1994;20:782–791.
6.
Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, Sakai N, Hirano K, Kawata S, Tarui S: Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology 1993;18:103–110.
7.
Irshad M, Dube R, Joshi YK: Impact of viral hepatitis on apo- and lipoprotein status in blood. Med Princ Pract 2007;16:310–314.
8.
Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C: Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006;13:56–61.
9.
Vere CC, Neagoe D, Streba CT, Prejbeanu I, Ianosi G, Comanescu V, Pirici D: Steatosis and serum lipid patterns in patients with chronic viral hepatitis: differences related to viral etiology. Rom J Morphol Embryol 2010;51:509–514.
10.
Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ: Serum lipids and their associations with viral levels and liver disease severity in a treatment-naive chronic hepatitis C type 1-infected cohort. J Viral Hepat 2011;18:e144–e152.
11.
Moritani M, Adachi K, Arima N, Takashima T, Miyaoka Y, Niigaki M, Furuta K, Sato S, Kinoshita Y: A study of arteriosclerosis in healthy subjects with HBV and HCV infection. J Gastroenterol 2005;40:1049–1053.
12.
Perales J, Angel Lasuncion M, Cano A, Martin-Scapa MA, Maties M, Herrera E: Changes in the lipid profile in chronic hepatopathies. Med Clin 1994;102:364–368.
13.
Tan TC, Crawford DH, Jaskowski LA, Murphy TM, Heritage ML, Subramaniam VN, Clouston AD, Anderson GJ, Fletcher LM: Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. Am J Physiol Gastrointest Liver Physiol 2011;301:G865–G876.
14.
Man EB, Kartin BL, Durlacher SH, Peters JP: The lipids of serum and liver in patients with hepatic diseases. J Clin Invest 1945;24:623–643.
15.
Petrides AS, Groop LC, Riely CA, DeFronzo RA: Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991;88:561–570.
16.
Onuegbu AJ, Olisekodiaka JM, Adebolu OE, Adesiyan A, Ayodele OE: Coffee consumption could affect the activity of some liver enzymes and other biochemical parameters in healthy drinkers. Med Princ Pract 2011;20:514–518.
17.
Al-Qabandi W, Owayed AF, Dhaunsi GS: Cellular oxidative stress and peroxisomal enzyme activities in pediatric liver transplant patients. Med Princ Pract 2012;21:264–270.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.